[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Ulm\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":671},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,42,70,96,122,142,159,185,212,240,260,286,312,336,360,390,415,461,488,521,553,585,605,626,650],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":14,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100410708","phase-3-phase-iii-study-of-induction-and-consolidation-chemotherapy-with-venetoclax-in-patients-with-newly-diagnosed-aml-or-mds-eb-2-100410708",false,"NCT04628026","Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2","Inclusion Criteria:\n\n1. Patients with newly diagnosed acute myeloid leukemia (AML) according to the International Consensus Classification (ICC).\n2. Age ≥ 18 and ≤ 75 years.\n3. Patients considered eligible for intensive chemotherapy.\n4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n5. Molecular analysis centrally performed in AMLSG and HOVON laboratories.\n6. Adequate renal function as evidenced by serum creatinine ≤ 2.0 × upper limit of norm (ULN) or creatinine clearance \\>40 mL\u002Fmin based on the Cockcroft-Gault glomerular filtration rate (GFR).\n7. Adequate hepatic function as evidenced by:\n\n   * Serum total bilirubin ≤ 2.5 × ULN unless considered due to Gilbert's disease, or leukemic involvement following approval by the Principal Investigators or Trial Coordinators of the study\n   * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 3.0 × ULN, unless considered due to leukemic involvement following approval by the Principal Investigators or Trial Coordinators.\n8. No prior chemotherapy for AML, except hydroxyurea for up to 14 days during the diagnostic screening phase for the control of peripheral leukemic blasts in patients with leukocytosis (e.g., white blood cell \\[WBC\\] counts \\> 25x109\u002FL); patients may have had previous treatment with erythroid stimulating agents (ESA) or hypomethylating agents (HMAs) for an antecedent phase of MDS; ESA and HMAs have to be stopped at least four weeks before start of study treatment.\n9. Patients must not have received a known strong or moderate CYP3A inducer 7 days before start of study treatment. Patients must have no known medical conditions requiring chronic therapy with moderate or strong CYP3A inducers.\n10. Female patient must either:\n\n    * Be of nonchildbearing potential:\n\n      * Postmenopausal (defined as at least 1 year without any menses)\n      * Documented surgically sterile (e.g. documented hysterectomy, bilateral oophorectomy, bilateral salpingectomy or congenital sterile) or status post hysterectomy (at least 1 month prior to screening)\n    * Or, if of childbearing potential (not surgically sterile and not postmenopausal)\n\n      * Not planning to become pregnant during the study and for 6 months after the final study drug administration\n      * And have a negative urine or serum pregnancy test at screening\n      * And, if heterosexually active, agree to consistently apply one highly effective\\* method of birth control in combination to a barrier method for the duration of the study and for 27 weeks after the final study drug administration\n\n        \\*Highly effective forms of birth control include\n      * Consistent and correct usage of established hormonal contraceptives that inhibit ovulation for at least 1 month prior to taking study drug. (hormonal contraception is only a highly effective method of birth control, if a combined \\[estrogen and progestogen containing\\] hormonal contraception or a progestogen-only hormonal contraception - both associated with inhibition of ovulation - is used.\n      * Established intrauterine device (IUD) or intrauterine system (IUS)\n      * Bilateral tubal occlusion\n      * Vasectomy - a vasectomy is highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.\n      * Male is sterile due to a bilateral orchiectomy.\n      * Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual activity during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient.\n\n        \\*List is not all inclusive. Prior to enrolment, the investigator is responsible for confirming patient will utilize highly effective forms of birth control in combination with a barrier method according to locally accepted standards during the protocol defined period.\n      * Female patient must agree not to breastfeed starting at screening and throughout the study period, and for 2 months and 1 week after the final study drug administration.\n      * Female patient must not donate ova starting at screening and throughout the study period, and for 27 weeks after the final study drug administration.\n11. Men must use a latex condom during any sexual contact with WOCBP, even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 27 weeks after the final study drug administration). In addition, their female partners of childbearing potential have to use a highly effective method of birth control.\n12. Male patient must not donate sperm starting at screening and throughout the study period and for 27 weeks after the final study drug administration.\n13. Able to understand and willing to sign an informed consent form (ICF).","ALL","18 Years","75 Years",{"count":20,"type":21},650,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3",[26],"Acute Myeloid Leukemia",[28],"adult patients","RECRUITING","2026-06-26",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2022-09-13",{"date":37,"type":21},"2032-02",{"name":39,"class":40},"University of Ulm","OTHER",91,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100634747","glucose-level-during-endurance-exercise-100634747","NCT07543705","Glucose-Level During Endurance Exercise","Glucose-Level During Endurance Exercise (GLEE Study): Influencing Factors and Mechanisms","GLEE","Inclusion Criteria:\n\n* BMI between 18.5 and 30 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* cardiovascular disease\n* vegan diet\n* drug or alcohol abuse\n* Drug therapy that raises or lowers blood sugar, e.g. steroids, antidiabetics, insulin or influences the autonomic nervous system\n* No consent to be informed about incidentally discovered pathological findings\n* Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion.",true,{"count":52,"type":21},100,"OBSERVATIONAL","As part of the mandatory annual assessment of physical fitness, soldiers are required to complete a standardized military march. A total of 100 healthy volunteer participants will be recruited from soldiers serving at the Bundeswehr Hospital Ulm. During this march, physiological and metabolic parameters will be assessed.\n\nAt baseline, anthropometric data and information on medical history, lifestyle, and fitness status will be collected, including a validated questionnaire on physical activity. Blood and urine samples will be obtained to determine routine laboratory and metabolic parameters, and body composition will be assessed using bioelectrical impedance analysis. In addition, selected sensors will be applied to continuously record physiological data.\n\nParticipants will then complete a 6 km march carrying 15 kg of equipment. After completion of the march, sensors will be removed and additional blood and urine samples will be collected to evaluate metabolic responses to physical exertion, including catecholamine levels.",[56],"Glucose Metabolism",[58,59,60],"glucose levels","endurance exercise","continuous glucose monitoring","2026-05-06",{"date":63,"type":33},"2026-05-11",{"date":65,"type":33},"2026-05-05",{"date":67,"type":21},"2028-06",{"name":39,"class":40},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":69},"100583501","hypercaloric-peg-nutrition-in-als-to-sustain-energy-homeostasis-100583501","NCT06877143","Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis","PEGASUS","Inclusion Criteria:\n\n* Possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria 1\n* Loss of ALS functional rating scale revised (ALSFRS-R) of ≥ 0.33 points per month since onset (first paresis) based on the formula: (48 - Score at Screening Visit) \u002F (Months between Onset and Screening Visit)\n* Nutrition via PEG\n* Age ≥18 years\n* Intake of a stable dose of riluzole for at least 4 weeks, or no riluzole\n* Capable of thoroughly understanding all information given and giving full informed consent according to GCP\n\nExclusion Criteria:\n\n* Previous participation in another interventional study within the preceding 4 weeks\n* Absence of adequate social support and cooperation, or personal motivation (in the judgment of the investigator) to complete the study satisfactorily\n* Pregnancy or breast-feeding females\n* Evidence of a major psychiatric disorder or clinically evident dementia",{"count":78,"type":21},76,[80],"NA","Weight loss is a known negative prognostic factor in amyotrophic lateral sclerosis (ALS). Over the last years, various interventional studies targeting the energy deficit in ALS yielded promising results; however,it is still unclear which kind of nutrition or nutritional supplement is most beneficial. Moreover, there is lack of evidence regarding interventions in patients with a PEG in later disease stages.In a pilot study conducted in 2013, it was demonstrated that body weight can be stabilized in ALS by applying either a fat-rich or carbohydrate-rich high-caloric food supplement. In 2014, Wills et al. conducted a placebo-controlled randomized controlled pilot study, which indicated that a carbohydrate-rich, hypercaloric diet, consisting in 125% of estimated energy requirements as determined by indirect calorimetry, in patients fed via percutaneous endoscopic gastrostomy was safe and well tolerated. Moreover, these patients showed longer survival than patients fed with a fat-rich, hypercaloric diet or an isocaloric diet . Hypercaloric, high-carbohydrate diet also showed beneficial effects on body weight and Body Mass Index . Although these results were promising, the low number of patients (n=24) was a severe limiting factor of this study. The aim of this study is to investigate the effect of a hypercaloric PEG nutrition, consisting of 120% of estimated calorie requierements, compared to an isocaloric nutrition. Individual energy requirement is determined by performing indirect calorimetry and activity questionnaire. The investigators hypothsize, that a hypercaloric PEG nutrition slows down disease progression as measured by neurofilament light chains (NfL) in serum after 6 months compared to placebo. Power calculation relies on the results of the lipids and calories for ALS (LIPCAL-ALS) study which tested the effect of an oral high-caloric fatty nutritional supplement in ALS. The study revealed that NfL serum values declined significantly in the intervention group while remaining stable in the placebo group over the course of the study. Assuming a similar effect size, we calculated that 76 patients had to be included in the current trial.",[83],"Amyotrophic Lateral Sclerosis (ALS)",[85,86,87,88],"ALS","PEG","hypercaloric nutrition","energy deficit","2026-04-30",{"date":61,"type":33},{"date":92,"type":33},"2025-03-01",{"date":94,"type":21},"2031-09-01",{"name":39,"class":40},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},"100537611","ultra-high-caloric-fatty-diet-in-als-100537611","NCT06280079","Ultra-high-caloric, Fatty Diet in ALS","Efficacy, Safety, and Tolerability of Ultra-high-caloric, Fatty Diet (UFD) in Amyotrophic Lateral Sclerosis (ALS)","LIPCAL-ALS II","Inclusion Criteria:\n\n* Possible, probable (clinically or laboratory supported) or definite amyotrophic lateral sclerosis according to the revised version of the El Escorial criteria\n* Disease duration (onset of first paresis or bulbar symptoms) \\\u003C 24 months\n* Loss of amyotrophic lateral sclerosis functional rating scale revised of ≥ 0.33 points\u002Fmonth based on the formula: (48 - myotrophic lateral sclerosis functional rating scale revised score at screening visit) \u002F (months between onset and screening visit)\n* Age ≥18 years.\n* Either continuously treated with a stable dose of riluzole, OR not treated with riluzole for the last 4 weeks prior to inclusion\n* Either continuously treated with a stable dose of edaravone, OR not treated with edaravone for the last 4 weeks prior to inclusion\n* Either continuously treated with a stable dose of sodium-phenylbutyrate\u002Ftaurursodiol, OR not treated with sodium-phenylbutyrate\u002Ftaurursodiol for the last 4 weeks prior to inclusion\n* Capable of thoroughly understanding all information given\n* full written informed consent according to good clinical practice\n\nExclusion Criteria:\n\n* Previous participation in another interventional study involving an active treatment within the preceding 4 weeks\n* Tracheostomy or continuous permanent ventilator dependence (\\>22 hours per day)\n* Pregnancy or breastfeeding\n* Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS\n* Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment.\n* Evidence of a major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms.\n* Liable to be not cooperative or comply with study requirements as assessed by the investigator, or unable to be reached in the case of emergency",{"count":105,"type":21},392,[80],"This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS).",[109],"Amyotrophic Lateral Sclerosis",[109,111,112,113],"High-caloric, high-fat nutrition","Survival","Randomized controlled trial",{"date":115,"type":33},"2026-05-01",{"date":117,"type":33},"2024-06-01",{"date":119,"type":21},"2028-01-01",{"name":39,"class":40},23,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":69},"100430177","phase-2-immunoadsorption-versus-immunoglobulins-for-treatment-of-chronic-inflammatory-demyelinating-polyneuropathy-cidp-100430177","NCT04881682","Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","IVITOC","Inclusion Criteria:\n\n* Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to European Federation of Neurological Societies (EFNS) guidelines\n* Disease duration of 3 years or less\n* Age 18 years or above\n* Previous treatment with methyl-prednisolone and insufficient therapeutic response as judged by the treating physician, or contraindications against methyl-prednisolone, or clinically significant side effects under methyl-prednisolone therapy as judged by the treating physician\n\nExclusion Criteria:\n\n* Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive protein (CRP) above 20 mg\u002Fl, or evidence of nitrite-positive urinary tract infection\n* Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment\n* immunoglobulin A deficiency\n* Other contraindications against immunoadsorption or intravenous immunoglobulins",{"count":130,"type":21},20,[132],"PHASE2","This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).",[135],"CIDP",{"date":115,"type":33},{"date":138,"type":33},"2023-05-01",{"date":140,"type":21},"2028-03-01",{"name":39,"class":40},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":69},"100429358","immunoadsorption-versus-plasma-exchange-for-treatment-of-guillain-barr-syndrome-gbs-100429358","NCT04871035","Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)","IPET-GBS","Inclusion Criteria:\n\n* Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome, Lancet neurology 2008)\n* age 18 years or above\n\nExclusion Criteria:\n\n* Clinical or laboratory (C-reactive protein 20 mg\u002Fl or above, or evidence of nitrite-positive urinary tract infection) evidence of manifest systemic infection\n* Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment\n* Other contraindications against immunoadsorption or plasma exchange",{"count":130,"type":21},"This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.",[152],"GBS",{"date":115,"type":33},{"date":155,"type":33},"2021-04-28",{"date":157,"type":21},"2027-09-01",{"name":39,"class":40},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":69},"100626481","imprinting-in-metabolic-diseases---identifying-epigenetic-mechanisms-in-human-gestational-diabetes-through-cell-free-dna-100626481","NCT07436195","Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA","Epi_GDM","Inclusion Criteria:\n\n* Pregnant women between 20 and 28 weeks of gestation\n* The father of the child is known and willing to participate in the study\n* No known underlying medical conditions in either parent\n* No fetal abnormalities detected in first-trimester screening, detailed fetal anatomy ultrasound, non-invasive prenatal testing (NIPT), or any additional prenatal examinations performed, if applicable\n* No known underlying diseases\n* Understanding and voluntary signing of a consent form before study- related examinations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Type 1 or type 2 diabetes mellitus\n* Pharmacological treatment affecting blood glucose levels (e.g., steroids, insulin)\n* Endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome \\[PCOS\\])\n* Current depression or other psychiatric disorders\n* Eating disorders\n* Regular use of medication during pregnancy\n* Pre-existing cardiovascular disease\n* Drug and\u002For alcohol abuse\n* Estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m²\n* C-reactive protein \\> 10 mg\u002Fl\n* Transaminase elevation of 2 times the upper norm\n* No consent to be informed about incidentally discovered pathological findings\n* Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion.",{"count":167,"type":21},80,"This clinical trials aims to investigate the impact of parental metabolism during pregnancy on fetal epigenetic signatures.\n\nThe metabolic profiles of both parents will be evaluated through a blood sample collected from the father and an oral glucose tolerance test administered to the pregnant mother. Additionally, epigenetic signatures will be assessed using parental blood samples. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.",[170],"Gestational Diabetes Mellitus (GDM)",[172,173,174,175,176],"epigenetics","pregnancy","parental metabolism","Cell-free DNA","gestational diabetes","2026-03-31",{"date":179,"type":33},"2026-04-07",{"date":181,"type":33},"2026-03-30",{"date":183,"type":21},"2028-07-01",{"name":39,"class":40},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":203,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":69},"100628786","the-importance-of-insulin-action-in-the-brain-for-the-immune-system-during-physical-activity-overweight-100628786","NCT07466173","The Importance of Insulin Action in the Brain for the Immune System During Physical Activity-Overweight","Inclusion Criteria:\n\n* BMI \\> 28 kg\u002Fm2\n* no known primary disease\n* hormonal contraception with a single-phase preparation\n\nExclusion Criteria:\n\n* alcohol or drug abuse\n* At screening: Hb \\\u003C 12 g\u002Fdl for women and Hb \\\u003C 14 g\u002Fdl for men\n* Any (clinical) condition that would endanger participant's safety or question scientific success according to a physician's opinion.","30 Years",{"count":193,"type":21},8,[80],"The goal of this clinical trial is to clarify the interaction of central insulin action and physical activity with the immune system. Therefore, participants will undergo bicycle spiroergometer tests. This approach will be compared between days with insulin delivery to the brain as nasal spray and days with placebo spray. In another trial (NCT06552130) lean participants already have been tested. Significant effects on circulating cytokines could be identified. In this amendment, overweight persons in which brain insulin resistance is expected will be tested.",[197],"Insulin Sensitivity",[199,200,201,202],"brain insulin action","autonomic nervous system","physical activity","immune system","NOT_YET_RECRUITING","2026-03-11",{"date":206,"type":33},"2026-03-16",{"date":208,"type":21},"2026-04",{"date":210,"type":21},"2027-06",{"name":39,"class":40},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":69},"100624515","impact-of-thyroid-hormones-on-human-glucose-and-energy-metabolism-100624515","NCT07410637","Impact of Thyroid Hormones on Human Glucose and Energy Metabolism","Inclusion Criteria:\n\n* patients with initial diagnosis of graves disease OR\n* patients with initial diagnosis of thyroid carcinoma\n\nExclusion Criteria:\n\n* contraindications for oral glucose tolerance test\n* Diabetes mellitus\n* Fasting glucose level ≥ 200 mg\u002FdL\n* Exogenous insulin administration with action at the time of the test\n* Current disease with activation of stress hormones\n* Post-aggressive metabolism\n* Acute infectious disease",{"count":219,"type":21},60,[80],"The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism.\n\nPatients will be included in whom thyroid hormone levels are intentionally changed by treatment. In patients with Graves' disease, thyroid hormone levels will be lowered using medication, while in patients with thyroid cancer, thyroid hormone levels will be raised using medication. Oral glucose tolerance tests will be performed before treatment and at two time points after treatment begins to assess metabolic effects.",[223,224],"Graves Disease","Thyroid Cancer",[226,227,228,229,230,231],"thyroid hormones","glucose metabolism","lipid metabolism","graves disease","thyroid cancer","hyperthyroidism","2026-02-12",{"date":234,"type":33},"2026-02-13",{"date":236,"type":33},"2026-02-04",{"date":238,"type":21},"2031-06",{"name":39,"class":40},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":69},"100570638","magnetic-resonance-imaging-in-metabolic-diseases-100570638","NCT06709846","Magnetic Resonance Imaging in Metabolic Diseases","Inclusion Criteria:\n\n* patients with metabolic diseases OR\n* healthy control participants without metabolic diseases\n* written consent\n\nExclusion Criteria:\n\n* History of traumatic brain injuries\n* preterm birth (≤34th week of pregnancy) of the study participant\n* history of brain surgery\n* structural brain changes (e.g., tumors, congenital abnormalities, etc.)\n* neurological developmental disorders (e.g., autism spectrum disorders, learning disabilities, intellectual disability)\n* epilepsy,\n* drug addiction\n* other severe neurological or severe psychiatric disorders (e.g., schizophrenia\n* pregnancy\n* acute clinically relevant inflammatory diseases\n* acute systemic or local infections\n* severe or etiologically unclear diseases depending on the principle investigators judgement\n* pre-existing intellectual impairment\n* significant limitations in language comprehension\n* absence of written consent\n* general exclusion criteria for MRI imaging (e.g., pacemaker systems, neurostimulators, cochlear implants)",{"count":247,"type":21},126,"This study aims to leverage structural, functional, and metabolic magnetic resonance imaging (MRI) of the brain to identify imaging features that correlate with clinical parameters. It is hypothesized that individuals with metabolic diseases exhibit distinct functional and structural brain differences compared to healthy controls. These differences may evolve over time due to changes in whole-body metabolism or body weight, influenced by factors such as the natural progression of the disease or therapeutic interventions. Additionally, potential brain changes may correlate with body composition metrics, such as the fat content of specific body compartments.\n\nThis is a prospective, single-center study conducted at Ulm University Hospital, designed to track the clinical and imaging histories of patients with metabolic diseases and compare them to healthy individuals. Eligible participants include adults (aged 18 and older) capable of providing informed consent. Recruitment will occur through routine clinical care or existing research studies. To provide a comprehensive understanding, the study will include both cross-sectional analyses and longitudinal follow-up of participants, integrating repeated assessments during routine medical visits.",[250],"Metabolic Diseases",[250,252,253],"Magnetic Resonance Imaging","Body Composition",{"date":234,"type":33},{"date":256,"type":33},"2025-02-08",{"date":258,"type":21},"2029-12",{"name":39,"class":40},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":269,"conditions":270,"keywords":273,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":285},"100152153","registry-study-on-patient-characteristics-biological-disease-profile-and-clinical-outcome-in-acute-myeloid-leukemia-and-related-neoplasms---the-biology-and-outcome-bio-project-100152153","NCT01252485","Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project","AMLSG BiO","Inclusion Criteria:\n\n* Patients with suspected diagnosis of acute myeloid leukemia and related neoplasms, newly diagnosed or relapsed\u002Frefractory, classified according to the International Consensus Classification\n* Age ≥ 18 years. There is no upper age limit.\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Severe neurological or psychiatric disorder interfering with ability to give an informed consent\n* No consent for registration, storage and processing of the individual patient and disease characteristics and course as well as information of the family physician about study participation\n* No consent for biobanking of patient's biological specimens and performance of analyses on stored material.",{"count":268,"type":21},50000,"This is a registry study in adult patients with newly diagnosed or refractory\u002Frelapsed myeloid neoplasms\n\nInvestigator's sites: 80-90 sites in Germany and Austria\n\nEstimated duration of observation of an individual patient:\n\n10 years maximum\n\nObjectives\n\n* To register all patients with AML and related neoplasms, newly diagnosed or relapsed\u002Frefractory in all AMLSG participating centers (completeness)\n* To perform rapid analyses of disease-related genetic markers (incidences, treatment recommendations)\n* To assess patient and family history, as well as patient characteristics\n* To evaluate treatment response (CR, CRh, CRi) and outcome data (event-free survival \\[EFS\\], relapse-free survival \\[RFS\\], cumulative incidence of relapse \\[CIR\\], cumulative incidence of death \\[CID\\], overall survival \\[OS\\])\n* To evaluate the impact of measurable residual disease (MRD) by different methods\n* To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)\n* To store biosamples from all patients (e.g., bone marrow, blood, plasma, normal tissue; e.g., skin biopsy, finger nails, hairs, sputum, or urine)",[271,272],"Acute Myeloid Leukemia (AML)","MDS\u002FAML",[274,275,276,272],"AML","Registry study","Biology and Outcome","2025-12-29",{"date":279,"type":33},"2026-01-05",{"date":281,"type":33},"2010-07-06",{"date":283,"type":21},"2044-12-31",{"name":39,"class":40},94,{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":293,"targetDuration":295,"studyType":53,"phases":4,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":69},"100615768","international-genetic-obesity-registry-100615768","NCT07296900","International Genetic Obesity Registry","iGO Registry","Inclusion Criteria:\n\n* Patients with\n\n  * genetically confirmed genetic obesity (ACMG classification 3-5, associated with obesity) and\u002For\n  * early onset severe obesity (BMI ≥ 120% 95th percentile or ≥ 35 kg\u002Fm2 before 5 years of age) if genetic testing was performed\n* Capable of understanding the aims of the protocol and to provide informed consent (for children and chronically incapacitated individuals, consent is given by their legal guardians)\n\nExclusion Criteria:\n\n* Not capable of understanding the aims of the protocol and to provide informed consent",{"count":294,"type":21},5000,"50 Years","Genetic obesity results from changes in specific genes that affect appetite regulation, metabolism, and fat storage. Its severity and associated health issues vary depending on the genetic cause. In some cases, hormonal imbalances, developmental delays, or other complications may also occur. Identifying the genetic cause is essential for personalized treatment and understanding potential symptoms.\n\nAs genetic obesity is rare, specialists often encounter few patients with diverse genetic backgrounds and clinical features. Therefore, collecting global data is crucial to improve our understanding of the condition's progression, complications, and treatment responses for each genetic subtype.\n\nTo support this, the International Genetic Obesity Registry (iGO Registry) has been established to gather detailed patient information on genetic obesity. This registry will help advance research and improve clinical care for affected individuals. It will collect data from routine outpatient visits, focusing on relevant diagnostic and treatment information on an international level.",[298],"Genetic Obesity",[300,301,302,303],"genetic obesity","patient registry","monogenic obesity","natural history","2025-12-08",{"date":306,"type":33},"2025-12-22",{"date":308,"type":33},"2025-11-17",{"date":310,"type":21},"2075-11",{"name":39,"class":40},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":320,"targetDuration":295,"studyType":53,"phases":4,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":335},"100328228","registry-for-patients-with-lipodystrophy-100328228","NCT03553420","Registry for Patients With Lipodystrophy","Osse Registry for Patients With Lipodystrophy Run by the European Consortium of Lipodystrophies (ECLip)","ECLip Registry","Inclusion Criteria:\n\n* lipodystrophy\n\nExclusion Criteria:\n\n* lipodystrophy due to anti-retroviral drugs",{"count":294,"type":21},"Given the lack of knowledge on lipodystrophies, the medical and social responsibility for the persons affected by it calls for the monitoring of the progression over long periods of time. Sensible clinical and basic research into rare diseases such as lipodystrophy is only possible in multi-location networks with sufficient case numbers. Also, reliable information on the incidence of certain manifestation patterns, health status, etc. is of utmost importance for health care and health policy in this rare disease.\n\nTherefore, the European Consortium of Lipodystrophies (ECLip), an association of European experts on lipodystrophy, has launched a registry (OSSE) for lipodystrophies which is committed to help to improve the research conditions by consolidating this kind of information in a registry.",[323,324],"Lipodystrophy Acquired","Lipodystrophy Congenital",[326],"lipodystrophy","2025-11-24",{"date":329,"type":33},"2025-12-02",{"date":331,"type":33},"2017-12-16",{"date":333,"type":21},"2068-01",{"name":39,"class":40},28,{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":69},"100604823","immunoadsorption-for-treatment-of-chronic-inflammatory-demyelinating-polyneuropathy-cidp-100604823","NCT07154524","Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","IFTOC","Inclusion Criteria:\n\n* Diagnosis of CIDP based on the EAN\u002FPNS Guidelines on Diagnosis and Treatment of CIDP13\n* age ≥ 18 years\n* Willing and capable of giving written informed consent\n* Currently receiving IVIg or MP treatment OR starting IVIg or MP treatment at baseline\n\nExclusion Criteria:\n\n* none",{"count":344,"type":21},140,"This study is designed as an explorative study aiming at exploring safety and efficacy of immunoadsorption (IA) in patients with Chronic Inflammatory Demyelinating Poly-neuropathy (CIDP) compared to intravenous immunoglobulins (IVIg) and methyl-prednisolone (MP). For this purpose, approximately 140 patients with CIDP will be included within the framework of the German multicenter network \"Kompetenznetz Peripherer Nerv\" (KKPNS).\n\nThe study will be purely observational. IA will be performed as an escalation therapy, i.e., in patients who did not respond to IVIg and\u002For MP treatment. Patients will be included in the study during ongoing IVIg or MP treatment and switched to IA during the 18-month observation period in case of an insufficient response. IA will be performed according to the therapeutic scheme of each participating center. A non-mandatory recommendation for number of sessions, treatment volumes, and frequency will be given (see below). Six-month follow-up visits including collection of standardized clini-cal data will be performed.",[347],"Chronic Inflammatory Demyelinating Polyneuropathy",[347,349,350,351],"Immunoadsorption","Long-term effects","therapy-refractory","2025-09-04",{"date":354,"type":33},"2025-09-11",{"date":356,"type":33},"2025-08-27",{"date":358,"type":21},"2029-08-27",{"name":39,"class":40},{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":22,"phases":369,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":69},"100586182","understanding-individual-variability-in-neuronal-signal-transmission-to-target-organs-in-health-and-disease-100586182","NCT06912048","Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease","CPB_Atropine","Inclusion Criteria:\n\n* Age: at least 18\n* BMI: 20 - 24.9 kg\u002Fm2 (for the healthy groups) or more than 28 kg\u002Fm2 (for the overweight groups)\n* For women: Hormonal contraception with a single-phase preparation (e.g. Nuvaring)\n* Understanding and voluntarily signing an informed consent form prior to study-related examinations\n\nExclusion Criteria:\n\n* Drug and\u002For alcohol abuse\n* smoking\n* Taking medication that affects blood sugar or addresses the central and\u002For autonomic nervous system (e.g. anti-epileptic drugs, beta blockers, dopamine agonists, antidepressants). Taking antihistamines.\n* Pre-existing cardiac conditions\n* Neurological pre-existing conditions\n* Known cardiac arrhythmia\n* Known allergies to ingredients, e.g. paracetamol and atropine\n* Known narrow-angle glaucoma\n* Known hyperthyroidism\n* Known diseases of the urinary tract or prostate\n* Pregnancy or breastfeeding\n* At screening: Hb \\\u003C 12 g\u002Fdl for women and Hb \\\u003C 14 g\u002Fdl for men\n* No consent to be informed about incidentally discovered pathological findings\n* Any (clinical) condition which, in the opinion of the physician, could jeopardize the safety of the\n* or would jeopardize the scientific success.\n* Liver dysfunction\n* Renal insufficiency",{"count":368,"type":21},52,[80],"The goal of this clinical trial is to evaluate the influence of parasympathetic transmission from the brain to different metabolic organs. This transmission can be blocked with the muscarinic antagonist atropine.\n\nParticipants will undergo an oral glucose tolerance test combined with a double tracer dilution technique either with atropine infusion or placebo.\n\nHealthy individuals and high-risk individuals will be compared to identify possible changes in signaling in high-risk groups. In addition, men and women will be included to take into account possible sex differences.",[372],"Autonomic Function",[374,200,375,376,377,378,379,380,381],"parasympathetic transmission","brain periphery crosstalk","metabolism","insulin sensitivity","insulin secretion","endogenous glucose production","sex differences","high risk population","2025-07-04",{"date":384,"type":33},"2025-07-10",{"date":386,"type":33},"2025-05-14",{"date":388,"type":21},"2027-05",{"name":39,"class":40},{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":22,"phases":399,"briefSummary":400,"conditions":401,"keywords":405,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":69},"100584718","texture-and-color-enhancement-imaging-txi-for-inflammation-assessment-in-patients-with-inflammatory-bowel-diseases-100584718","NCT06892990","Texture and Color Enhancement Imaging (TXI) for Inflammation Assessment in Patients With Inflammatory Bowel Diseases","Texture and Color Enhancement Imaging (TXI) for Real-time Prediction of Histologic Changes in Patients With Inflammatory Bowel Diseases: a Comparison of White Light Endoscopy (WLE) Versus TXI","COLORIZE","Inclusion Criteria:\n\n* Histologically confirmed inflammatory bowel disease (ulcerative colitis or Crohn\\'s disease)\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Post (procto-) colectomy\n* Endoscopically impassable stenosis in the left hemi-colon\n* ASA status \\> 2 points\n* BBPS \\< 6 points (or \\< 2 points per segment)\n* Severe coagulation disorder\n* Pregnancy, lactation",{"count":167,"type":21},[80],"In the context of the COLORIZE study, it is being tested whether the endoscopic light mode Texture and Color Enhancement Imaging (TXI) is non-inferior to the standard White Light Endoscopy (WLE) in assessing inflammatory activity in patients with Inflammatory Bowel Disease (IBD). For this purpose, ileocolonoscopy is performed on patients diagnosed with IBD, and standardized image documentation will be carried out in both WLE and TXI modes. Step biopsies are taken, and clinically validated, endoscopic, and histological scores are used.",[402,403,404],"Inflammatory Bowel Diseases","Colitis, Ulcerative","Crohn Disease",[406,402],"TXI","2025-04-29",{"date":409,"type":33},"2025-05-02",{"date":411,"type":33},"2024-05-08",{"date":413,"type":21},"2025-09",{"name":39,"class":40},{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":422,"targetDuration":424,"studyType":53,"phases":4,"briefSummary":425,"conditions":426,"keywords":438,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":69},"100569332","fertility-protection-for-children-adolescents-and-young-adults-100569332","NCT06692868","Fertility Protection for Children, Adolescents and Young Adults","FeProCAYA","Children, adolescents, young adults with a diagnosis of cancer before the age of 21 years\n\nor\n\nChildren, adolescents, young adults undergoing SCT for a malignant or non-malignant condition before the age of 21 years\n\ntreated at the Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.",{"count":423,"type":21},2000,"20 Years","This study focuses on improving fertility preservation and long-term care for children, adolescents, and young adults (CAYA) undergoing cancer treatments or stem cell transplantation. These treatments can harm fertility, and ensuring that patients receive the right support and follow-up care is critical.\n\nThe main study goals are:\n\n1. Understanding Fertility Risks: Researchers aim to identify factors that predict fertility problems after cancer treatments, such as the type of therapy, hormone levels, body composition, or genetic predispositions.\n2. Addressing Patient and Family Needs: The program will explore the concerns, needs, and challenges faced by young patients and their parents regarding fertility. It will also examine how these issues affect their quality of life.\n3. Improving Clinical Care: Current practices in fertility preservation and counseling will be studied to identify gaps and improve care structures.\n\nTo achieve these goals, the program will:\n\n* Create a database to collect and analyze medical data from patients before, during, and after cancer treatments.\n* Study the prevalence and long-term effects of fertility problems in young patients.\n* Document medical interventions like fertility preservation methods (e.g., freezing eggs or sperm) and treatments for late effects.\n* Assess patients' and families' fertility-related quality of life and their informational needs.\n\nUltimately, the project aims to establish an interdisciplinary center to support fertility preservation and improve the quality of care for young patients facing cancer and its treatments.",[427,428,429,430,431,432,433,434,435,436,437],"Stem Cell Transplant","Stem Cell Transplantation","Oncological Outcomes","Oncological Patients","Oncological Children","Fertility","Fertility Protection","Endocrinological Late-effects","Paediatric Oncology","CAYA","Survivors",[420,439,440,441,442,443,444,445,446,447,448,449,450,451,452,436],"Fertility protection","Endocrinological follow-up after oncological disease","children","fertility","adolescents","young adults","TYA","teenagers and young adults","paediatric oncology","follow-up care","endocrinological late-effects","survivors","stem cell transplant","stem cell transplantation","2025-01-13",{"date":455,"type":33},"2025-01-16",{"date":457,"type":33},"2024-12-09",{"date":459,"type":21},"2044-11",{"name":39,"class":40},{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":469,"minAge":17,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":22,"phases":472,"briefSummary":473,"conditions":474,"keywords":476,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":69},"100564297","hilotherapy-for-prevention-of-chemotherapy-induced-peripheral-polyneuropathy-100564297","NCT06627348","Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy","Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy - a Unicentric, Prospective-controlled, Randomized Clinical Trial for Comparison of Local Hilotherapy Vs. No Therapy to Prevent Peripheral Polyneuropathy During Taxan-based Chemotherapy Regimen","HiPPo","Inclusion Criteria:\n\n* Written consent for participation in this trail\n* Age ≥18 years\n* Female\n* Breast or genital cancer of the woman\n* Planned application of a Taxan-based chemotherapy regimen (Paclitaxel, Nab-Paclitaxel, Docetaxel) independent of the therapy line\n* Taxan- and Platin-naivity\n* Sufficient knowledge of the German language to assure an adequat survey of patient's history\n\nExclusion Criteria:\n\n* pre-existing peripheral polyneuropathy\n* chemotherapy with taxan- and\u002For carboplatin-based regimens in a preceding therapy\n* Existence of one of the following diseases: Diabetes mellitus (of any type), neurological diseases that are involving peripheral nerve damage (e.g. Multiple Sclerosis, Amytrophic lateral sclerosis, Parkinson's disease), chronic pain syndrome, Cryoglobulinemia, cold hemagglutination, cold hives \u002F cold contact hives, Raynaud's disease, significant peripheral artery disease,\n* Lack of knowledge of German\n* Males","FEMALE",{"count":471,"type":21},150,[80],"Prospective study of hilotherapy of hands and feet as prevention of chemotherapy-induced peripheral polyneuropathy induced by Taxan-based chemotherapy regimen that are used in the therapy of breast cancer and genital malignoma of the women.",[475],"Equipment and Supplies",[477,478,479],"Chemo-induced Peripheral Polyneuropathy","Taxan","Hilotherapy","2024-10-02",{"date":482,"type":33},"2024-10-04",{"date":484,"type":33},"2024-04-17",{"date":486,"type":21},"2027-03-31",{"name":39,"class":40},{"id":489,"slug":490,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":496,"enrollmentInfo":497,"targetDuration":499,"studyType":53,"phases":4,"briefSummary":500,"conditions":501,"keywords":506,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":69},"100453964","immune-modulation-by-exosomes-in-covid-19-100453964","NCT05191381","Immune Modulation by Exosomes in COVID-19","Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19","IMECOV19","Inclusion Criteria:\n\n* Critically ill COVID-19 patients with lung dysfunction\n* COVID-19 WHO severity degree \\>= 4, ARDS (WHO Definition 13 March 2020)\n* Body weight \\> 50 kg\n* Informed consent\n\nExclusion Criteria:\n\n* Pregnant or breast feeding women","90 Years",{"count":498,"type":21},40,"12 Months","Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.",[502,503,504,505],"COVID-19","Critical Illness","Hypercytokinemia","Lung Fibrosis",[502,507,504,508,509,510,511,512],"Critical illness","Exosomes","Mesenchymal stem cells","Tissue reconstitution","Immune modulation","Sepsis","2024-01-16",{"date":515,"type":33},"2024-01-17",{"date":517,"type":33},"2021-12-22",{"date":519,"type":21},"2026-12-31",{"name":39,"class":40},{"id":522,"slug":523,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":531,"conditions":532,"keywords":540,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":69},"100369752","burden-mortality-and-supply-costs-in-intensive-care-unit-patients-100369752","NCT04094428","Burden, Mortality and Supply Costs in Intensive Care Unit Patients","Burden, Mortality and Supply Costs in Intensive Care Unit Patients. Health Services Research.","PLV_Ulm","Inclusion Criteria:\n\n* All patients dying on the ICU and all patients staying for at least 72 hours on the ICU\n\nExclusion Criteria:\n\n* No",{"count":530,"type":21},700,"This study systematically observes in a pragmatic trail under real world conditions the association between strategies of therapy (maximal therapy, withhold, withdraw) and treatment success in three endpoint related initial risk groups (high, intermediate, low risk) regarding three endpoints (burden, mortality and supply costs).",[533,534,535,536,537,538,539],"Burden, Dependency","Mortality","End-of-life Care","Intensive Care Unit","Critically Ill Patient","Frailty","Multiple Organ Failure",[541,542,543,544,545,546,539],"burden","mortality","end-of-life care","intensive care unit","critically ill patient","frailty",{"date":515,"type":33},{"date":549,"type":33},"2019-10-21",{"date":551,"type":21},"2026-09-30",{"name":39,"class":40},{"id":554,"slug":555,"hasResults":11,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":496,"enrollmentInfo":561,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":562,"conditions":563,"keywords":572,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":69},"100289166","monocyte-profiles-in-critically-ill-patients-with-pseudomonas-aeruginosa-sepsis-100289166","NCT03044223","Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis","Phenotypical Und Functional Characterization of Macrophages in Critically Ill Patients With Pseudomonas Aeruginosa Induced Sepsis","MIPSA","Inclusion Criteria:\n\n* age \\> 18 years\n* critically ill patients with sepsis\n* microbiologically proven infection with Pseudomonas aeruginosa\n\nExclusion Criteria:\n\n* life expectancy \\\u003C 24 hours\n* participation in other studies",{"count":52,"type":21},"The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.",[564,565,566,567,568,569,512,570,571],"Pseudomonas Infections","Pseudomonas Septicemia","Pseudomonas; Pneumonia","Pseudomonal Bacteraemia","Pseudomonas Urinary Tract Infection","Pseudomonas Gastrointestinal Tract Infection","Sepsis, Severe","Critically Ill",[573,545,574,575,576,577,578],"pseudomonas aeruginosa","sepsis","monocyte","macrophage","cytokine","severity of disease",{"date":515,"type":33},{"date":581,"type":4},"2014-08",{"date":583,"type":21},"2026-12",{"name":39,"class":40},{"id":586,"slug":587,"hasResults":11,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":496,"enrollmentInfo":593,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":603,"locationsCount":604},"100202604","hemophagocytosis-in-critically-ill-adult-patients-100202604","NCT01913938","Hemophagocytosis in Critically Ill Adult Patients","Hemophagocytosis in Critically Ill Adult Patients With Cytopenias","HCIAP","Inclusion Criteria:\n\n* age \\> 18 years\n* critically ill adult patients\n* leukopenia and thrombocytopenia\n* rhG-CSF therapy\n\nExclusion Criteria:\n\n* life expectancy \\\u003C 24 hours\n* inclusion in other studies\n* trauma patients with reanimation on scene or immediately dying on hospital admission\n* pregnancy\n* hematologic disorder, malignancy\n* high dose corticosteroid treatment or chemotherapy",{"count":498,"type":21},"The purpose of the study is to find out whether non-responsiveness to therapeutic recombinant human granulocyte colony-stimulation factor (rhG-CSF) is associated with hemophagocytosis in critically ill adult patients with cytopenias.",[596],"Hemophagocytosis",[598],"Hemophagocytosis, adults, rhG-CSF",{"date":515,"type":33},{"date":601,"type":4},"2013-07",{"date":583,"type":21},{"name":39,"class":40},2,{"id":606,"slug":607,"hasResults":11,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":611,"targetDuration":613,"studyType":53,"phases":4,"briefSummary":614,"conditions":615,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":625},"100295421","german-mpn-registry-for-bcr-abl-1-negative-myeloid-neoplasms-study-group-ulm-100295421","NCT03125707","German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)","Inclusion Criteria:\n\nBoth female and male patients meeting the mentioned inclusion criteria will be included in this registry, because the risk to get a myeloid neoplasm does not depend on a patient's gender. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the registry:\n\n* Patients with BCR-ABL 1-myeloid neoplasia according to WHO classification or IWG MRI criteria\n* Age ≥ 18 years. There is no upper age limit.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Severe neurological or psychiatric disorder interfering with ability to give an informed consent\n* No consent for registration, storage and handling of the personal data",{"count":612,"type":21},2172,"25 Years","To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 \u002F 2016 classification) in participating centers\n\nTo store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases)\n\nTo perform morphologic and genetic analyses\n\nTo assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables\n\nTo assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)\n\nTo assess quality of life",[616],"BCR-ABL1-Negative Myeloid Neoplasms","2023-05-17",{"date":619,"type":33},"2023-05-19",{"date":621,"type":4},"2013-05",{"date":623,"type":21},"2045-09",{"name":39,"class":40},30,{"id":627,"slug":628,"hasResults":11,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":632,"eligibilityCriteria":633,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":634,"targetDuration":636,"studyType":53,"phases":4,"briefSummary":637,"conditions":638,"keywords":640,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":69},"100261719","registry-study-on-epidemiological-and-biological-disease-profile-as-well-as-clinical-outcome-in-patients-with-low-grade-gliomas-100261719","NCT02686229","Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas","Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas: The LOG-Glio-Project","LoG-Glio","Inclusion Criteria:\n\n* Patients with radiological suspected diagnosis of a low grade glioma\n* Age ≥ 18 years. There is no upper age limit.\n\nExclusion Criteria:\n\n* Severe neurological or psychiatric disorder interfering with ability to give an informed consent\n* No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation\n* No consent for bio-banking of patient's biological specimens and performance of analyses on stored material.",{"count":635,"type":21},300,"10 Years","The LoG-Glio-Registry is based on a network of german hospitals gathering radiological, clinical, epidemiological and molecular data on all patients diagnosed with a low grade glioma.",[639],"Glioma",[641],"Low grade glioma, registry, neurosurgery, brain tumor","2023-05-10",{"date":644,"type":33},"2023-05-11",{"date":646,"type":33},"2015-11-15",{"date":648,"type":21},"2036-12",{"name":39,"class":40},{"id":651,"slug":652,"hasResults":11,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":658,"targetDuration":636,"studyType":53,"phases":4,"briefSummary":659,"conditions":660,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":666,"completionDateStruct":668,"leadSponsor":670,"locationsCount":69},"100370114","pacareg-a-multicenter-registry-trial-in-pancreatic-ductal-adencarcinoma-100370114","NCT04099134","PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma","PaCaReg: A Multicenter Registry Trial for the Assessement of Clinical, Epidemiological and Biological Profiles in Patients With Pancreatic Ductal Adenocarcinoma","PaCaReg","Inclusion Criteria:\n\n* Treatment naive histologically or cytologically proven pancreatic ductal adenocarcinoma (PDAC) or highly suspicious diagnosis (only pre-curative-intended resection)\n* Age =\\>18 years\n* written informed consent\n\nExclusion Criteria:\n\n* papillary cancer\n* neuroendocrine pancreatic tumors",{"count":294,"type":21},"PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma",[661,662],"Pancreas Adenocarcinoma","Pancreas Cancer","2019-09-23",{"date":665,"type":33},"2019-09-25",{"date":667,"type":33},"2018-10-10",{"date":669,"type":21},"2029-10",{"name":39,"class":40},""]